NTLA Intellia Therapeutics, Inc. - Common Stock
$12,68
Kurs · Aug 20, 2026
Fundamentaldaten per Aug 6, 2026
52W-Spanne
$8–$28
23% of range
Analystenbewertung
BUY
24 analysts
Kursziel
$24
+89% upside
P/E (TTM)
-3.4
ROE
-59.5%
Nettogewinnmarge
-609.8%
Über Intellia Therapeutics, Inc. - Common Stock Unternehmensübersicht von Wikipedia
Intellia Therapeutics Inc. ist ein US-amerikanisches Pharmaunternehmen mit Sitz in Cambridge (Massachusetts), Vereinigte Staaten. Der Hauptzweck des Unternehmens ist die Bearbeitung von Genomen.
Mehr lesen
Intellia Therapeutics Inc. ist ein US-amerikanisches Pharmaunternehmen mit Sitz in Cambridge (Massachusetts), Vereinigte Staaten. Der Hauptzweck des Unternehmens ist die Bearbeitung von Genomen.
Pharmazie
Das Unternehmen konzentriert sich auf die Entwicklung von Therapeutika unter Verwendung biologischer Werkzeuge namens CRISPR und Cas9. Das CRISPR/Cas9-Genomeditiersystem umfasst zwei Komponenten: a) das Cas9-Protein und b) die Leit-RNA-Sequenz. Das Cas9-Protein wirkt wie eine molekulare Schere, die den natürlichen zellulären Reparaturprozess initiiert, um ein Gen auszuschalten, zu reparieren oder einzufügen. Die Leit-RNA-Sequenz erkennt und lenkt das Cas9 zu einer spezifischen Ziel-Desoxyribonukleinsäure (DNA) -Sequenz. Die Sentinel-In-vivo-Programme des Unternehmens konzentrieren sich auf die Verwendung von Lipid-Nanopartikeln (LNPs) zur Abgabe des CRISPR/Cas9-Komplexes an die Leber. Die Abteilung des Unternehmens eXtellia Therapeutics konzentriert sich auf die Anwendung der CRISPR/Cas9-Genombearbeitung in den Bereichen Immunonkologie sowie Autoimmun- und Entzündungskrankheiten. Die Tochtergesellschaft des Unternehmens ist Intellia Securities Corp.
Es unterhält Partnerschaften mit Novartis, Regeneron Pharmaceuticals, Ospedale San Raffaele, Teneobio und GEMoaB Monoclonals.
Geschichte
Intellia Therapeutics wurde im Mai 2014 gegründet, um Biopharmazeutika mit CRISPR zu entwickeln.
Das Unternehmen wurde von Atlas Venture und Novartis unterstützt. Der Gründungs-CEO war Nessan Bermingham von Atlas und Chief Scientific Officer (CSO) war John Leonard, ehemals CSO von AbbVie. Zu den an der Gründung beteiligten akademischen Wissenschaftlern gehörten Rodolphe Barrangou, Rachel Haurwitz, Luciano Marraffini, Erik Sontheimer und Derrick Rossi. Das geistige Eigentum rund um CRISPR wurde von Anfang an angefochten. Intellia lizenzierte Patente von Caribou Biosciences, die von Jennifer Doudna angemeldet wurden.
Im Januar 2015 schlossen Novartis und Intellia einen Vertrag, durch den Novartis das Recht erhielt, CRISPR für sein CAR-T-Programm zu verwenden, und die Unternehmen stimmten einer Zusammenarbeit zu über Möglichkeiten zur Verwendung von CRISPR zur Behandlung von Krankheiten mit hämatopoetischen Stammzellen, einschließlich Beta-Thalassämie und Sichelzellenerkrankungen. Intellia gründete eine Abteilung namens eXtellia Therapeutics, um die CAR-T-Zusammenarbeit mit Novartis zu verwalten.
Zu den Wettbewerbern von Intellia gehörten im Februar 2015 CRISPR Therapeutics, Editas Medicine und Horizon Discovery. Unter den großen Pharmaunternehmen hatte AstraZeneca das breiteste Spektrum an Zusammenarbeit mit anderen Firmen bzgl. CRISPR.
Im Dezember 2016 zog das Unternehmen in seinen neuen Hauptsitz in Cambridge, Massachusetts, um. Zu diesem Zeitpunkt hatte die Firma eine Arzneimittelabgabetechnologie für Lipidnanopartikel lizenziert. Damit sollte die Freisetzung, die Absorption und Verteilung von Wirkstoffen geregelt werden. Es sollte so die Abgabe des CRISPR-Arzneimittels an die Leber unterstützt werden.
Im April 2017 ging Intellia eine Partnerschaft mit Regeneron Pharmaceuticals ein. Die Unternehmen beschlossen gemeinsam, neue Produkte zu entwickeln. Im Rahmen der Partnerschaft erhielt Regeneron das ausschließliche Recht, die CRISPR-Plattform von Intellia für bis zu 10 Wirkstofftargets zu verwenden, von denen bis zu fünf Produkt-Wirkstoffe für Therapien außerhalb der Leber bestimmt waren.
== Einzelnachweise ==
Quelle: Wikipedia, CC BY-SA 4.0 · Auf Wikipedia ansehen ↗
NTLA Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$12.68
Marktkapitalisierung
$1.53B
P/E (TTM)
-3.4
EPS (TTM)
$-3.81
Umsatz (TTM)
$68M
Dividendenrendite
—
ROE
-59.5%
Verschuldungsgrad
—
52W-Spanne
$8 – $28
NTLA Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Configure
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz & Nettoergebnis
$68M
2016-12-31
→
2025-12-31
EPS
$-3.81
2020-12-31
→
2025-12-31
Freier Cashflow
$-396M
2016-12-31
→
2025-12-31
Margen
-609.8%
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
Kennzahl
5-Jahres-Trend
NTLA
Peer-Median
P/E (TTM)
-3.4
—
P/S (TTM) (K/V (TTM))
22.6
22.9
P/B (K/B)
2.3
2.5
Price / FCF (Kurs / FCF)
-3.9
—
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
Kennzahl
5-Jahres-Trend
NTLA
Peer-Median
Operating Margin (Betriebsgewinnmarge)
-651.7%
—
Net Profit Margin (Nettogewinnmarge)
-609.8%
-618.0%
ROA
-40.6%
-40.9%
ROE
-59.5%
-47.9%
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
Kennzahl
5-Jahres-Trend
NTLA
Peer-Median
Current Ratio (Liquiditätsgrad)
5.1
9.0
Quick Ratio
4.4
—
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
Kennzahl
5-Jahres-Trend
NTLA
Peer-Median
Revenue YoY (Umsatz YoY)
16.9%
—
Revenue CAGR 3Y (Umsatz CAGR 3J)
9.1%
—
Revenue CAGR 5Y (Umsatz CAGR 5J)
3.1%
—
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
Kennzahl
5-Jahres-Trend
NTLA
Peer-Median
NTLA Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
KAUF
24 Analysten
- Starker Kauf 4 16,7%
- Kauf 9 37,5%
- Halten 8 33,3%
- Verkauf 2 8,3%
- Starker Verkauf 1 4,2%
12-Monats-Kursziel
17 Analysten · 2026-08-20
Median
$17.00
Mittelwert
$23.94
Jetzt
$12.68
Tief
$8.00
Hoch
$61.00
Median-Ziel
$17.00
+34,1%
Mittelwert-Ziel
$23.94
+88,9%
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
0.11%
| Zeitraum | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|
| 30. Juni 2026 | $-0.80 | $-0.82 | 0.02% |
| 31. März 2026 | $-0.81 | $-0.93 | 0.12% |
| 31. Dezember 2025 | $-0.83 | $-0.97 | 0.14% |
| 30. September 2025 | $-0.92 | $-1.02 | 0.10% |
| 30. Juni 2025 | $-0.98 | $-1.04 | 0.06% |
| 31. März 2025 | $-1.10 | $-1.31 | 0.21% |
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| NTLA | $1.05B | -2.4 | 16.9% | -609.8% | -59.5% | — |
| TSHA | $1.57B | -16.2 | 17.3% | -1115.3% | -44.0% | — |
| DMRA | — | — | 38.3% | -17981.1% | -167.0% | — |
| PURR | — | — | — | — | — | — |
| SNDX | $1.84B | -6.4 | 627.8% | -165.6% | -257.1% | — |
| RXRX | $2.16B | -2.8 | 26.9% | -863.4% | -62.9% | — |
| ANAB | — | -105.4 | 157.0% | — | — | — |
| ABSI | $529M | -4.2 | -38.2% | -4113.7% | -63.5% | — |
| BCAX | $953M | -6.7 | — | — | -33.0% | — |
| FBRX | $353M | -5.8 | 106.6% | -2555.2% | -86.9% | — |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung 16
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $68M | $58M | $36M | $52M | $33M | $58M | $43M | $30M | $26M | $16M | |
| Cost of Revenue | · | · | · | · | $0 | $0 | $0 | $0 | · | · | |
| R&D Expense | $389M | $466M | $435M | $420M | $230M | $150M | $108M | $89M | $68M | $32M | |
| SG&A Expense | $120M | $126M | $116M | $90M | $71M | $44M | $41M | $32M | $28M | $17M | |
| Operating Expenses | $509M | $592M | $552M | $510M | $301M | $195M | $149M | $121M | $96M | $49M | |
| Operating Income | $-441M | $-534M | $-515M | $-458M | $-268M | $-137M | $-106M | $-91M | $-70M | $-32M | |
| Interest Income | $29M | $48M | $50M | $9M | $1M | $2M | $7M | $6M | $2M | $525.0K | |
| Other Non-op | $28M | $15M | $34M | $-16M | $-42.0K | $2M | $7M | · | · | · | |
| Pretax Income | · | · | · | · | · | · | · | · | $-68M | $-32M | |
| Income Tax | $0 | · | · | · | · | · | · | · | · | $0 | |
| Net Income | $-413M | $-519M | $-481M | $-474M | $-268M | $-134M | $-474M | $-85M | $-68M | $-32M | |
| EPS (Basic) | $-3.81 | $-5.25 | $-5.42 | $-6.16 | $-3.78 | $-2.40 | · | · | · | · | |
| EPS (Diluted) | $-3.81 | $-5.25 | $-5.42 | $-6.16 | $-3.78 | $-2.40 | · | · | · | · | |
| Shares (Basic) | 108,376,000 | 98,849,000 | 88,770,000 | 76,972,000 | 70,894,000 | 55,987,000 | · | · | · | · | |
| Shares (Diluted) | 108,376,000 | 98,849,000 | 88,770,000 | 76,972,000 | 70,894,000 | 55,987,000 | · | · | · | · | |
| EBITDA | $-431M | $-524M | $-506M | $-451M | $-261M | $-130M | $-101M | $-86M | · | $-32M |
Bilanz 22
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $155M | $189M | $227M | $524M | $123M | $160M | $57M | $59M | $341M | $273M | |
| Short-term Investments | $294M | $412M | $685M | $669M | $625M | $437M | $222M | $255M | · | · | |
| Receivables | $9M | $9M | $36M | $4M | $2M | $2M | $5M | $8M | $10M | $6M | |
| Prepaid Expense | $68M | $30M | $50M | $20M | $19M | $17M | $5M | $3M | $4M | $2M | |
| Current Assets | $528M | $640M | $998M | $1.22B | $769M | $617M | $289M | $325M | $355M | $281M | |
| PP&E (Net) | $18M | $27M | $33M | $28M | $21M | $16M | $18M | $17M | $15M | $11M | |
| PP&E (Gross) | $76M | $77M | $73M | $61M | $47M | $35M | $32M | $26M | $20M | $12M | |
| Accum. Depreciation | $59M | $50M | $40M | $33M | $26M | $19M | $14M | $9M | $4M | $1M | |
| Other Non-current Assets | · | · | · | · | · | $5M | $3M | $5M | $6M | $7M | |
| Total Assets | $842M | $1.19B | $1.30B | $1.52B | $1.29B | $676M | $334M | $347M | $376M | $299M | |
| Accounts Payable | $20M | $15M | $7M | $5M | $10M | $10M | $4M | $3M | $2M | $5M | |
| Accrued Liabilities | $50M | $55M | $67M | $61M | $43M | $26M | $13M | $11M | $8M | $6M | |
| Current Liabilities | $104M | $111M | $115M | $127M | $126M | $64M | $36M | $41M | $31M | $31M | |
| Capital Leases | $67M | $190M | $97M | $114M | $65M | $34M | $13M | · | · | · | |
| Other Non-current Liabilities | · | · | · | · | $0 | · | · | $13.0K | $168.0K | $293.0K | |
| Total Liabilities | $171M | $319M | $251M | $285M | · | · | · | · | · | · | |
| Common Stock | $12.0K | $10.0K | $9.0K | $9.0K | $7.0K | $7.0K | $5.0K | $5.0K | $4.0K | $4.0K | |
| Retained Earnings | $-2.59B | $-2.18B | $-1.66B | $-1.18B | $-703M | $-435M | $-301M | $-201M | $-121M | $-54M | |
| AOCI | $1M | $605.0K | $-2M | $-7M | $-3M | $1.0K | $261.0K | $-28.0K | · | · | |
| Stockholders' Equity | $671M | $872M | $1.05B | $1.24B | $1.04B | $527M | $270M | $278M | $301M | $210M | |
| Liabilities + Equity | $842M | $1.19B | $1.30B | $1.52B | $1.29B | $676M | $334M | $347M | $376M | $299M | |
| Shares Outstanding | 116,317,060 | 102,029,594 | 92,997,158 | 87,103,007 | 74,485,883 | 66,234,056 | 50,198,044 | 45,224,480 | 42,384,623 | 36,018,540 |
Cashflow 11
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $10M | $10M | $9M | $8M | $7M | $6M | $6M | $4M | $3M | $1M | |
| Stock-based Comp | $80M | $154M | $134M | $91M | $47M | $20M | $15M | $17M | $15M | $7M | |
| Other Non-cash | $-72M | $6M | $-56M | $42M | $-11M | $58M | $-24M | $3M | · | · | |
| Operating Cash Flow | $-395M | $-349M | $-394M | $-333M | $-225M | $-50M | $-103M | $-61M | $-65M | $36M | |
| CapEx | $1M | $6M | $14M | $14M | $13M | $4M | $7M | $6M | $10M | $6M | |
| Investing Cash Flow | $228M | $126M | $-31M | $160M | $-551M | $-214M | $25M | $-261M | $-10M | $-6M | |
| Stock Issued | $128M | $177M | $120M | · | $1.82B | $1.12B | $72M | $29M | $141M | $171M | |
| Net Stock Activity | $128M | · | · | · | $1.82B | $1.12B | $72M | $29M | · | $171M | |
| Financing Cash Flow | $131M | $186M | $130M | $583M | $737M | $372M | $76M | $40M | $143M | $167M | |
| Net Change in Cash | $-35M | $-38M | $-295M | $410M | $-39M | $107M | $-2M | $-282M | $68M | $197M | |
| Free Cash Flow | $-396M | $-355M | $-408M | $-347M | $-238M | $-53M | $-110M | $-68M | · | $30M |
Rentabilität 6
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -651.7% | -923.1% | -1420.5% | -879.0% | -810.4% | -235.5% | -246.8% | -298.6% | · | · | |
| Net Margin | -609.8% | -896.8% | -1326.5% | -909.8% | -810.5% | -231.5% | -230.9% | -280.4% | · | · | |
| EBITDA Margin | -637.2% | -905.3% | -1395.8% | -864.5% | -789.5% | -224.6% | -233.8% | -283.9% | · | · | |
| ROA | -40.6% | -41.7% | -34.1% | -33.7% | -27.2% | -26.6% | -29.2% | -23.6% | · | -16.6% | |
| ROE | -59.5% | -56.6% | -46.1% | -46.0% | -24.9% | -31.3% | -36.5% | -31.5% | · | -33.5% | |
| ROIC | · | · | · | · | · | · | · | · | · | -15.3% |
Liquidität & Solvenz 2
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.1 | 5.8 | 8.7 | 9.6 | 6.1 | 9.6 | 8.1 | 8.0 | · | 9.2 | |
| Quick Ratio | 4.4 | 5.5 | 8.2 | 9.5 | 6.0 | 9.3 | 8.0 | 1.6 | · | 9.1 |
Effizienz 2
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | · | · | |
| Receivables Turnover | 7.5 | 6.7 | 1.7 | 13.4 | 14.6 | 34.7 | 10.5 | 3.4 | · | · |
Wachstumsraten 3
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 16.9% | 59.6% | -30.4% | 57.7% | -43.0% | · | · | · | · | · | |
| Revenue CAGR 3Y | 9.1% | 20.5% | -14.5% | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 3.1% | · | · | · | · | · | · | · | · | · |
Bewertung (TTM) 10
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $68M | $58M | $36M | $52M | $33M | $58M | $43M | $30M | $26M | $16M | |
| Net Income TTM | $-413M | $-519M | $-481M | $-474M | $-268M | $-134M | $-474M | $-85M | $-68M | $-32M | |
| Market Cap | $1.05B | $1.19B | $2.84B | $3.04B | $8.81B | $2.73B | $736M | $617M | · | $472M | |
| P/E | -2.4 | -2.2 | -5.6 | -5.7 | -31.3 | -22.7 | · | · | · | · | |
| P/S | 15.5 | 20.6 | 78.2 | 58.3 | 266.5 | 47.1 | 17.1 | 20.3 | · | 28.7 | |
| P/B | 1.6 | 1.4 | 2.7 | 2.5 | 8.5 | 5.2 | 2.7 | 2.2 | · | 2.3 | |
| P / Tangible Book | 1.6 | 1.4 | 2.7 | 2.5 | 8.5 | 5.2 | · | · | · | · | |
| P / Cash Flow | -2.6 | -3.4 | -7.2 | -9.1 | -39.1 | -54.7 | -7.1 | -10.1 | · | 13.1 | |
| P / FCF | -2.6 | -3.4 | -6.9 | -8.8 | -37.0 | -51.0 | -6.7 | -9.1 | · | 15.8 | |
| Earnings Yield | -42.4% | -45.0% | -17.8% | -17.7% | -3.2% | -4.4% | · | · | · | · |
Gewinn- und Verlustrechnung 13
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8M | $15M | $23M | $14M | $14M | $17M | $13M | $9M | $7M | $29M | $-2M | $12M | $14M | $13M | $14M | $13M | |
| R&D Expense | $83M | $81M | $89M | $95M | $97M | $108M | $117M | $123M | $114M | $112M | $109M | $114M | $115M | $97M | $100M | $97M | |
| SG&A Expense | $38M | $35M | $33M | $31M | $27M | $29M | $32M | $31M | $32M | $31M | $29M | $29M | $31M | $27M | $24M | $22M | |
| Operating Expenses | $120M | $116M | $122M | $125M | $124M | $137M | $149M | $154M | $146M | $143M | $138M | $143M | $146M | $125M | $124M | $119M | |
| Operating Income | $-113M | $-101M | $-99M | $-111M | $-110M | $-121M | $-136M | $-145M | $-139M | $-114M | $-140M | $-131M | $-132M | $-112M | $-110M | $-106M | |
| Interest Income | $6M | $5M | $6M | $7M | $7M | $9M | $11M | $12M | $12M | $13M | $12M | $13M | $13M | $12M | $5M | $2M | |
| Other Non-op | $6M | $4M | $3M | $10M | $9M | $6M | $8M | $9M | $-8M | $7M | $8M | $9M | $9M | $9M | $-3M | $-8M | |
| Net Income | $-107M | $-96M | $-96M | $-101M | $-101M | $-114M | $-129M | $-136M | $-147M | $-107M | $-132M | $-122M | $-124M | $-103M | $-113M | $-113M | |
| EPS (Basic) | $-0.80 | $-0.81 | $-0.81 | $-0.92 | $-0.98 | $-1.10 | $-1.27 | $-1.34 | $-1.52 | $-1.12 | $-1.47 | $-1.38 | $-1.40 | $-1.17 | $-1.38 | $-1.49 | |
| EPS (Diluted) | $-0.80 | $-0.81 | $-0.81 | $-0.92 | $-0.98 | $-1.10 | $-1.27 | $-1.34 | $-1.52 | $-1.12 | $-1.47 | $-1.38 | $-1.40 | $-1.17 | $-1.38 | $-1.49 | |
| Shares (Basic) | 133,480,000 | 118,490,000 | -209,044,000 | 110,188,000 | 103,732,000 | 103,500,000 | -194,630,000 | 101,002,000 | 96,975,000 | 95,502,000 | -175,832,000 | 88,645,000 | 88,185,000 | 87,772,000 | -149,649,000 | 76,047,000 | |
| Shares (Diluted) | 133,480,000 | 118,490,000 | -209,044,000 | 110,188,000 | 103,732,000 | 103,500,000 | -194,630,000 | 101,002,000 | 96,975,000 | 95,502,000 | -175,832,000 | 88,645,000 | 88,185,000 | 87,772,000 | -149,649,000 | 76,047,000 | |
| EBITDA | $-111M | $-98M | · | $-109M | $-107M | $-118M | · | $-145M | $-139M | $-111M | · | $-131M | $-132M | $-110M | · | $-106M |
Bilanz 20
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $106M | $135M | $155M | $193M | $156M | $127M | $189M | $120M | $131M | $172M | $227M | $168M | $172M | $294M | $524M | $141M | |
| Short-term Investments | $332M | $241M | $294M | $318M | $303M | $377M | $412M | $538M | $560M | $619M | · | $687M | $736M | $639M | · | $687M | |
| Receivables | $7M | $9M | $9M | $11M | $11M | $11M | $9M | $9M | $12M | $36M | $36M | $6M | $5M | $5M | $4M | $4M | |
| Prepaid Expense | $83M | $81M | $68M | $60M | $25M | $37M | $30M | $44M | $54M | $56M | · | $32M | $26M | $25M | · | $27M | |
| Current Assets | $528M | $466M | $528M | $582M | $496M | $551M | $640M | $711M | $757M | $884M | · | $893M | $940M | $964M | · | $859M | |
| PP&E (Net) | $15M | $16M | $18M | $20M | $23M | $25M | $27M | $29M | $30M | $32M | · | $34M | $33M | $32M | · | $27M | |
| PP&E (Gross) | · | · | $76M | · | · | · | $77M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $59M | · | · | · | $50M | · | · | · | · | · | · | · | · | · | |
| Total Assets | $857M | $759M | $842M | $925M | $899M | $986M | $1.19B | $1.17B | $1.19B | $1.26B | · | $1.24B | $1.32B | $1.42B | · | $1.08B | |
| Accounts Payable | $12M | $19M | $20M | $13M | $10M | $12M | $15M | $13M | $19M | $14M | · | $4M | $12M | $7M | · | $4M | |
| Accrued Liabilities | $44M | $38M | $50M | $41M | $42M | $41M | $55M | $51M | $45M | $43M | · | $58M | $50M | $45M | · | $58M | |
| Current Liabilities | $79M | $76M | $104M | $94M | $95M | $113M | $111M | $106M | $105M | $98M | · | $92M | $100M | $103M | · | $131M | |
| Capital Leases | $50M | $61M | $67M | $71M | $76M | $80M | $190M | $82M | $87M | $92M | · | $101M | $106M | $110M | · | $84M | |
| Total Liabilities | $129M | $138M | $171M | $177M | $184M | $206M | $319M | $211M | $220M | $223M | · | $206M | · | · | · | · | |
| Common Stock | $14.0K | $12.0K | $12.0K | $12.0K | $10.0K | $10.0K | $10.0K | $10.0K | $10.0K | $10.0K | · | $9.0K | $9.0K | $9.0K | · | $8.0K | |
| Retained Earnings | $-2.79B | $-2.69B | $-2.59B | $-2.49B | $-2.39B | $-2.29B | $-2.18B | $-2.05B | $-1.91B | $-1.77B | · | $-1.53B | $-1.40B | $-1.28B | · | $-1.06B | |
| AOCI | $-1M | $-240.0K | $1M | $990.0K | $653.0K | $1M | $605.0K | $3M | $-1M | $-947.0K | · | $-4M | $-4M | $-3M | · | $-9M | |
| Stockholders' Equity | $728M | $621M | $671M | $748M | $715M | $780M | $872M | $963M | $971M | $1.04B | $1.05B | $1.04B | $1.10B | $1.19B | $1.24B | $825M | |
| Liabilities + Equity | $857M | $759M | $842M | $925M | $899M | $986M | $1.19B | $1.17B | $1.19B | $1.26B | · | $1.24B | $1.32B | $1.42B | · | $1.08B | |
| Shares Outstanding | 140,018,200 | 120,447,521 | 116,317,060 | 115,787,285 | 105,330,693 | 103,539,685 | 102,029,594 | 101,796,365 | 98,289,150 | 96,333,373 | 92,997,158 | 89,097,821 | 88,347,634 | 88,095,779 | 87,103,007 | 76,587,947 |
Cashflow 10
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $2M | $2M | $2M | $2M | $2M | $2M | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Stock-based Comp | $18M | $13M | $17M | $20M | $22M | $22M | $40M | $40M | $41M | $34M | $35M | $35M | $36M | $27M | $25M | $25M | |
| Restructuring | · | · | · | · | $6M | $6M | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | $-37M | · | · | · | $-59M | · | · | · | $-50M | · | · | · | $-36M | · | · | |
| Operating Cash Flow | $-83M | $-117M | $-69M | $-77M | $-100M | $-149M | $-85M | $-85M | $-58M | $-121M | $-93M | $-101M | $-90M | $-109M | $-90M | $-79M | |
| CapEx | $2M | $79.0K | $126.0K | $29.0K | $239.0K | $735.0K | $981.0K | $1M | $1M | $3M | $2M | $4M | $4M | $4M | $4M | $4M | |
| Investing Cash Flow | $-142M | $66M | $28M | $-741.0K | $107M | $94M | $152M | $-8M | $-24M | $6M | $46M | $80M | $-35M | $-122M | $-30M | $48M | |
| Financing Cash Flow | $196M | $34M | $2M | $115M | $15M | $0 | $2M | $82M | $41M | $60M | $106M | $19M | $3M | $2M | $506M | $24M | |
| Net Change in Cash | $-29M | $-17M | $-40M | $37M | $22M | $-55M | $69M | $-10M | $-41M | $-55M | $59M | $-3M | $-122M | $-229M | $386M | $-7M | |
| Free Cash Flow | · | $-117M | · | · | · | $-150M | · | · | · | $-123M | · | · | · | $-113M | · | · |
Rentabilität 5
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1472.2% | -668.1% | · | -808.9% | -772.2% | -726.6% | · | -1589.0% | -1998.6% | -394.0% | · | -1093.3% | -973.5% | -888.1% | · | -795.5% | |
| Net Margin | -1392.3% | -639.5% | · | -735.2% | -710.8% | -687.6% | · | -1489.5% | -2112.6% | -371.3% | · | -1019.2% | -909.8% | -818.1% | · | -853.5% | |
| EBITDA Margin | -1444.8% | -653.4% | · | -791.5% | -754.6% | -711.5% | · | -1589.0% | -1998.6% | -385.3% | · | -1093.3% | -973.5% | -871.9% | · | -795.5% | |
| ROA | -12.1% | -11.0% | · | -9.7% | -9.7% | -10.2% | · | -11.2% | -11.7% | -8.0% | · | -10.5% | -10.2% | -7.9% | · | -9.4% | |
| ROE | -14.8% | -13.7% | · | -11.8% | -12.0% | -12.6% | · | -13.6% | -14.2% | -9.7% | · | -13.1% | -12.5% | -9.6% | · | -11.7% |
Liquidität & Solvenz 2
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.6 | 6.1 | · | 6.2 | 5.2 | 4.9 | · | 6.7 | 7.2 | 9.0 | · | 9.7 | 9.4 | 9.3 | · | 6.6 | |
| Quick Ratio | 5.6 | 5.0 | · | 5.6 | 4.9 | 4.6 | · | 6.3 | 6.7 | 8.5 | · | 9.4 | 9.1 | 9.1 | · | 6.3 |
Effizienz 2
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 0.8 | 1.5 | · | 1.4 | 1.2 | 0.7 | · | 1.2 | 0.8 | 1.4 | · | 2.3 | 3.4 | 3.8 | · | 4.1 |
Bewertung (TTM) 10
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $51M | $60M | · | $54M | $47M | $62M | · | $57M | $61M | $67M | · | $51M | $53M | $51M | · | $46M | |
| Net Income TTM | $-405M | $-413M | · | $-453M | $-498M | $-504M | · | $-512M | $-500M | $-456M | · | $-462M | $-441M | $-464M | · | $-432M | |
| Market Cap | $2.37B | $1.54B | · | $2.00B | $988M | $736M | · | $2.09B | $2.20B | $2.65B | · | $2.82B | $3.60B | $3.28B | · | $4.29B | |
| P/E | -4.8 | -3.4 | · | -4.0 | -1.9 | -1.4 | · | -3.8 | -4.1 | -5.4 | · | -5.8 | -7.6 | -6.3 | · | -9.7 | |
| P/S | 46.7 | 25.9 | · | 37.2 | 21.0 | 11.9 | · | 36.7 | 35.8 | 39.5 | · | 54.7 | 67.3 | 64.2 | · | 93.7 | |
| P/B | 3.3 | 2.5 | · | 2.7 | 1.4 | 0.9 | · | 2.2 | 2.3 | 2.6 | · | 2.7 | 3.3 | 2.8 | · | 5.2 | |
| P / Tangible Book | 3.3 | 2.5 | · | 2.7 | 1.4 | 0.9 | · | 2.2 | 2.3 | 2.6 | · | 2.7 | 3.3 | 2.8 | · | 5.2 | |
| P / Cash Flow | · | -13.2 | · | · | · | -4.9 | · | · | · | -22.0 | · | · | · | -30.0 | · | · | |
| P / FCF | · | -13.2 | · | · | · | -4.9 | · | · | · | -21.5 | · | · | · | -29.0 | · | · | |
| Earnings Yield | -20.7% | -29.7% | · | -25.1% | -52.7% | -71.5% | · | -26.1% | -24.2% | -18.4% | · | -17.2% | -13.2% | -16.0% | · | -10.3% |
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
Gewinn- und Verlustrechnung
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Umsatz | $68M | $58M | $36M | $52M | $33M |
| Betriebsgewinnmarge % | -651.7% | -923.1% | -1420.5% | -879.0% | -810.4% |
| Nettoergebnis | $-413M | $-519M | $-481M | $-474M | $-268M |
| Verwässerte EPS | $-3.81 | $-5.25 | $-5.42 | $-6.16 | $-3.78 |
Bilanz
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Liquiditätsgrad | 5.1 | 5.8 | 8.7 | 9.6 | 6.1 |
| Quick Ratio | 4.4 | 5.5 | 8.2 | 9.5 | 6.0 |
Cashflow
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Freier Cashflow | $-396M | $-355M | $-408M | $-347M | $-238M |
Neueste Nachrichten Aktuelle Schlagzeilen über dieses Unternehmen
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
📊
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das ➕ neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Institutionelle Eigentümer (13F) 373 Einreicher · $2.1B gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 59 (-10 vs. Vorquartal) | 28 (-14 vs. Vorquartal) | 138 (+14 vs. Vorquartal) | 82 (+12 vs. Vorquartal) | +32.0M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| ARK Investment Management LLC | $285.536.575 | 16.875.684 | 13,62% | Aktien |
| STATE STREET CORP | $156.255.980 | 9.234.987 | 7,46% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $124.064.225 | 7.332.401 | 5,92% | Aktien |
| VANGUARD GROUP INC | $109.190.661 | 12.145.791 | 5,21% | Aktien |
| D. E. Shaw & Co., Inc. | $109.021.025 | 6.443.323 | 5,20% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $102.003.675 | 6.028.586 | 4,87% | Aktien |
| TWO SIGMA INVESTMENTS, LP | $88.582.088 | 5.235.348 | 4,23% | Aktien |
| RA CAPITAL MANAGEMENT, L.P. | $76.595.588 | 4.526.926 | 3,65% | Aktien |
| FMR LLC | $69.353.456 | 4.098.904 | 3,31% | Aktien |
| REGENERON PHARMACEUTICALS, INC. | $62.654.675 | 3.702.995 | 2,99% | Aktien |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $55.510.459 | 3.280.760 | 2,65% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $52.683.658 | 3.112.991 | 2,51% | Aktien |
| Sumitomo Mitsui Trust Group, Inc. | $49.026.191 | 2.897.529 | 2,34% | Aktien |
| Amova Asset Management Americas, Inc. | $49.026.191 | 2.897.529 | 2,34% | Aktien |
| DIMENSIONAL FUND ADVISORS LP | $41.173.682 | 2.433.433 | 1,96% | Aktien |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | $34.962.744 | 2.066.356 | 1,67% | Aktien |
| Contrarius Group Holdings Ltd | $33.082.458 | 1.955.228 | 1,58% | Aktien |
| ARMISTICE CAPITAL, LLC | $25.380.000 | 1.500.000 | 1,21% | Aktien |
| RENAISSANCE TECHNOLOGIES LLC | $23.688.068 | 1.400.004 | 1,13% | Aktien |
| GOLDMAN SACHS GROUP INC | $22.647.589 | 1.338.510 | 1,08% | Aktien |
| TWO SIGMA ADVISERS, LP | $21.093.390 | 2.346.317 | 1,01% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $20.438.362 | 1.207.941 | 0,98% | Aktien |
| Ghisallo Capital Management LLC | $20.304.000 | 1.200.000 | 0,97% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $18.227.916 | 1.077.300 | 0,87% | Kaufoption |
| Woodline Partners LP | $18.194.905 | 1.075.349 | 0,87% | Aktien |
| BAKER BROS. ADVISORS LP | $15.739.525 | 930.232 | 0,75% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $15.585.367 | 921.121 | 0,74% | Aktien |
| Connor, Clark & Lunn Investment Management Ltd. | $15.210.454 | 898.963 | 0,73% | Aktien |
| IQ EQ FUND MANAGEMENT (IRELAND) Ltd | $13.162.880 | 777.948 | 0,63% | Aktien |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $12.284.884 | 726.057 | 0,59% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $10.958.729 | 647.679 | 0,52% | Aktien |
| Marex Group Ltd | $10.551.312 | 623.600 | 0,50% | Aktien |
| BNP PARIBAS FINANCIAL MARKETS | $9.776.799 | 577.825 | 0,47% | Aktien |
| RAYMOND JAMES FINANCIAL INC | $9.428.010 | 557.211 | 0,45% | Aktien |
| BlackRock, Inc. | $9.138.594 | 540.106 | 0,44% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $8.311.544 | 491.226 | 0,40% | Aktien |
| BANK OF AMERICA CORP /DE/ | $7.682.391 | 454.042 | 0,37% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $7.267.140 | 429.500 | 0,35% | Verkaufsoption |
| Caption Management, LLC | $6.757.848 | 399.400 | 0,32% | Kaufoption |
| Point72 Asset Management, L.P. | $6.741.994 | 398.463 | 0,32% | Aktien |
| Birchview Capital, LP | $6.520.968 | 385.400 | 0,31% | Aktien |
| CITADEL ADVISORS LLC | $6.321.312 | 373.600 | 0,30% | Verkaufsoption |
| Vestmark Advisory Solutions, Inc. | $6.024.028 | 356.030 | 0,29% | Aktien |
| Casdin Capital, LLC | $6.006.600 | 355.000 | 0,29% | Aktien |
| GFS Advisors, LLC | $5.815.143 | 130 | 0,28% | Aktien |
| FIRST TRUST ADVISORS LP | $5.749.534 | 339.807 | 0,27% | Aktien |
| PINNACLE ASSOCIATES LTD | $5.736.286 | 339.024 | 0,27% | Aktien |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | $5.531.030 | 326.893 | 0,26% | Aktien |
| CAPITAL FUND MANAGEMENT S.A. | $5.048.589 | 298.380 | 0,24% | Aktien |
| Trexquant Investment LP | $5.045.104 | 298.174 | 0,24% | Aktien |
| JANE STREET GROUP, LLC | $5.030.316 | 297.300 | 0,24% | Verkaufsoption |
| JANE STREET GROUP, LLC | $4.999.860 | 295.500 | 0,24% | Kaufoption |
| UBS Group AG | $4.967.509 | 293.588 | 0,24% | Kaufoption |
| Swiss National Bank | $4.350.132 | 257.100 | 0,21% | Aktien |
| CITADEL ADVISORS LLC | $4.238.460 | 250.500 | 0,20% | Kaufoption |
| Opaleye Management Inc. | $4.230.000 | 250.000 | 0,20% | Aktien |
| AMERICAN CENTURY COMPANIES INC | $4.044.151 | 239.016 | 0,19% | Aktien |
| CITIGROUP INC | $3.814.732 | 225.457 | 0,18% | Aktien |
| DEUTSCHE BANK AG\ | $3.562.506 | 210.550 | 0,17% | Aktien |
| Susquehanna Portfolio Strategies, LLC | $3.544.080 | 209.461 | 0,17% | Aktien |
| XTX Topco Ltd | $3.408.297 | 201.436 | 0,16% | Aktien |
| DIADEMA PARTNERS LP | $3.384.000 | 200.000 | 0,16% | Kaufoption |
| WASATCH ADVISORS LP | $3.357.096 | 261.864 | 0,16% | Aktien |
| LPL Financial LLC | $3.239.842 | 191.480 | 0,15% | Aktien |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $3.226.187 | 190.673 | 0,15% | Aktien |
| ELEVATION POINT WEALTH PARTNERS, LLC | $3.184.463 | 188.207 | 0,15% | Aktien |
| SECTOR GAMMA AS | $3.133.195 | 185.177 | 0,15% | Aktien |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $3.100.844 | 183.265 | 0,15% | Aktien |
| RHUMBLINE ADVISERS | $2.990.177 | 176.725 | 0,14% | Aktien |
| UBS Group AG | $2.881.797 | 170.319 | 0,14% | Aktien |
| CITADEL ADVISORS LLC | $2.786.927 | 164.712 | 0,13% | Aktien |
| WOLVERINE TRADING, LLC | $2.759.652 | 163.100 | 0,13% | Kaufoption |
| Rafferty Asset Management, LLC | $2.700.111 | 159.581 | 0,13% | Aktien |
| BLAIR WILLIAM & CO/IL | $2.582.195 | 152.612 | 0,12% | Aktien |
| Bank of New York Mellon Corp | $2.538.795 | 150.047 | 0,12% | Aktien |
| Point72 Asset Management, L.P. | $2.431.404 | 143.700 | 0,12% | Kaufoption |
| BARCLAYS PLC | $2.430.001 | 143.617 | 0,12% | Aktien |
| MARSHALL WACE, LLP | $2.377.903 | 140.538 | 0,11% | Aktien |
| Jefferies Financial Group Inc. | $2.233.440 | 132.000 | 0,11% | Kaufoption |
| WELLS FARGO & COMPANY/MN | $1.991.281 | 117.688 | 0,10% | Aktien |
| TUDOR INVESTMENT CORP ET AL | $1.978.083 | 116.908 | 0,09% | Aktien |
| GROUP ONE TRADING LLC | $1.925.970 | 113.828 | 0,09% | Aktien |
| AMERIPRISE FINANCIAL INC | $1.892.012 | 111.821 | 0,09% | Aktien |
| ALLIANCEBERNSTEIN L.P. | $1.837.747 | 143.350 | 0,09% | Aktien |
| OPPENHEIMER & CO INC | $1.818.105 | 107.453 | 0,09% | Aktien |
| ENVESTNET ASSET MANAGEMENT INC | $1.780.170 | 105.211 | 0,08% | Aktien |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $1.772.480 | 138.259 | 0,08% | Aktien |
| Cubist Systematic Strategies, LLC | $1.762.421 | 102.051 | 0,08% | Aktien |
| Elmwood Wealth Management, Inc. | $1.741.813 | 102.944 | 0,08% | Aktien |
| Deuterium Capital Management, LLC | $1.692.000 | 100.000 | 0,08% | Aktien |
| MORGAN STANLEY | $1.641.240 | 97.000 | 0,08% | Aktien |
| D.A. DAVIDSON & CO. | $1.616.537 | 95.540 | 0,08% | Aktien |
| Headlands Technologies LLC | $1.594.710 | 94.250 | 0,08% | Aktien |
| Havemeyer Place LP | $1.522.580 | 89.987 | 0,07% | Aktien |
| PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | $1.493.308 | 88.257 | 0,07% | Aktien |
| VANGUARD ASSET MANAGEMENT, Ltd | $1.486.405 | 87.849 | 0,07% | Aktien |
| Engineers Gate Manager LP | $1.433.598 | 84.728 | 0,07% | Aktien |
| Caption Management, LLC | $1.433.124 | 84.700 | 0,07% | Aktien |
| LAZARD ASSET MANAGEMENT LLC | $1.427.693 | 84.379 | 0,07% | Aktien |
| JONES FINANCIAL COMPANIES LLLP | $1.419.835 | 85.122 | 0,07% | Aktien |
Unternehmensinsider 31 Insider · 17 Führungskräfte · 16 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| John M. Leonard | President and CEO | 1. März 2026 A | 1.169.739 | 0 | 4 | $-1.150.869 |
| Nessan Bermingham | President & CEO | 12. Dezember 2017 A | 458.250 | 0 | 0 | $0 |
| Edward J Dulac III | EVP, Chief Financial Officer | 22. Juli 2026 S | 148.175 | 0 | 3 | $-234.186 |
| Glenn Goddard | EVP, Chief Financial Officer | 1. März 2024 A | 69.213 | 0 | 0 | $0 |
| Graeme Bell | EVP, Chief Financial Officer | 28. März 2018 M | 21.400 | 0 | 0 | $0 |
| Andrew Schiermeier | EVP, Chief Operating Officer | 3. März 2021 A | 16.656 | 0 | 0 | $0 |
| Dube Michael P | VP, Chief Accounting Officer | 1. Juli 2026 S | 66.886 | 0 | 3 | $-104.363 |
| Birgit C Schultes | EVP, Chief Scientific Officer | 1. März 2026 A | 137.733 | 0 | 2 | $-78.898 |
| Eliana Clark | EVP, Chief Technical Officer | 1. März 2026 A | 93.864 | 0 | 2 | $-95.997 |
| David Lebwohl | EVP, Chief Medical Officer | 1. März 2026 A | 131.192 | 0 | 1 | $-109.627 |
| James Basta | EVP, General Counsel | 1. März 2026 A | 156.794 | 0 | 2 | $-112.444 |
| Derek Hicks | EVP, Chief Business Officer | 3. Januar 2025 S | 59.878 | 0 | 0 | $0 |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | 3. Januar 2025 S | 77.388 | 0 | 0 | $0 |
| Jose E Rivera | EVP, General Counsel | 1. April 2021 M | 162.388 | 0 | 0 | $0 |
| Nicole Heifner | SVP, Accounting | 6. Januar 2017 A | — | 0 | 0 | $0 |
| David V Morrissey | SVP, Platform & Delivery Tech | 6. Januar 2017 A | — | 0 | 0 | $0 |
| Thomas M. Barnes | SVP, R&D eXtellia | 6. Januar 2017 A | — | 0 | 0 | $0 |
| Muna Bhanji | Direktor | 9. Juni 2026 A | 36.403 | 0 | 0 | $0 |
| Georgia Keresty | Direktor | 9. Juni 2026 A | 41.083 | 0 | 0 | $0 |
| Jesse Goodman | Direktor | 9. Juni 2026 A | 33.559 | 0 | 0 | $0 |
| William J Chase | Direktor | 9. Juni 2026 A | 143.893 | 1 | 0 | $1.003.000 |
| Brian Goff | Direktor | 9. Juni 2026 A | 32.609 | 0 | 0 | $0 |
| Frank Verwiel | Direktor | 9. Juni 2026 A | 35.148 | 0 | 0 | $0 |
| Fred Cohen | Direktor | 9. Juni 2026 A | 216.653 | 1 | 0 | $1.402.500 |
| John F Crowley | Direktor | 14. Juni 2023 A | 11.716 | 0 | 0 | $0 |
| Caroline Dorsa | Direktor | 14. Juni 2022 A | 12.701 | 0 | 0 | $0 |
| FORMELA JEAN FRANCOIS | Direktor | 14. Juni 2022 A | 7.291 | 0 | 0 | $0 |
| Perry A Karsen | Direktor | 17. Dezember 2020 M | 5.000 | 0 | 0 | $0 |
| Moncef Slaoui | Direktor | 25. Juli 2017 A | — | 0 | 0 | $0 |
| GORDON CARL L | Direktor | 18. Mai 2017 A | 2.662.180 | 0 | 0 | $0 |
| Rachel E. Haurwitz | Direktor | 11. Mai 2016 C | 5.593.846 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
Aktivisten & 5%+-Eigentümer 2 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Novartis Institutes for BioMedical Research, Inc., Novartis AG ×6 Einreichungen | 22. Januar 2021 | — | Erste Einreichung | — | SEC |
| OrbiMed Advisors LLC, OrbiMed Capital GP V LLC, OrbiMed Global Healthcare GP LLC ×4 Einreichungen | 16. Februar 2018 | — | Erste Einreichung | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF-Besitz Gehalten von 56 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| ARKG · ARK ETF Trust | 3,82% | 3.498.399 NS | 30. April 2026 | N-PORT |
| ARKK · ARK ETF Trust | 2,06% | 9.902.541 NS | 30. April 2026 | N-PORT |
| GNOM · Global X Funds | 1,59% | 63.134 NS | 31. Mai 2026 | N-PORT |
| BBC · ETFis Series Trust I | 1,10% | 30.599 NS | 30. April 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,56% | 215.007 NS | 30. April 2026 | N-PORT |
| IDNA · iShares Trust | 0,50% | 97.334 SH | 19. August 2026 | Täglich |
| HRTS · Tema ETF Trust | 0,38% | 13.892 NS | 31. Mai 2026 | N-PORT |
| FSCC · Federated Hermes ETF Trust | 0,24% | 47.560 NS | 31. Mai 2026 | N-PORT |
| FYC · First Trust Exchange-Traded AlphaDE… | 0,23% | 182.175 NS | 30. April 2026 | N-PORT |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,15% | 117.485 SH | 19. August 2026 | Täglich |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,13% | 325.025 SH | 19. August 2026 | Täglich |
| FYX · First Trust Exchange-Traded AlphaDE… | 0,12% | 108.015 NS | 30. April 2026 | N-PORT |
| IBB · iShares Trust | 0,11% | 980.941 SH | 19. August 2026 | Täglich |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,11% | 7.731 SH | 19. August 2026 | Täglich |
| AVSC · AMERICAN CENTURY ETF TRUST | 0,10% | 201.195 NS | 31. Mai 2026 | N-PORT |
| IWN · iShares Trust | 0,10% | 1.268.426 SH | 19. August 2026 | Täglich |
| GINN · Goldman Sachs ETF Trust | 0,10% | 14.553 NS | 31. Mai 2026 | N-PORT |
| BIB · ProShares Trust | 0,08% | 4.369 NS | 31. Mai 2026 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,08% | 43.955 NS | 30. April 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,07% | 777.703 SH | 19. August 2026 | Täglich |
| VBK · VANGUARD INDEX FUNDS | 0,06% | 1.798.189 SH | 19. August 2026 | Täglich |
| IWM · iShares Trust | 0,05% | 3.484.420 SH | 19. August 2026 | Täglich |
| ISCV · iShares Trust | 0,05% | 29.274 SH | 19. August 2026 | Täglich |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,05% | 16.989 NS | 30. April 2026 | N-PORT |
| RSSL · Global X Funds | 0,05% | 48.088 NS | 30. April 2026 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,04% | 10.659 SH | 19. August 2026 | Täglich |
| ITWO · ProShares Trust | 0,04% | 5.225 NS | 31. Mai 2026 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0,04% | 633.495 NS | 31. Mai 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,04% | 385.133 NS | 30. April 2026 | N-PORT |
| TECB · iShares Trust | 0,03% | 13.023 SH | 19. August 2026 | Täglich |
| VXF · VANGUARD INDEX FUNDS | 0,03% | 1.604.561 SH | 19. August 2026 | Täglich |
| VB · VANGUARD INDEX FUNDS | 0,03% | 3.110.166 SH | 19. August 2026 | Täglich |
| VHT · VANGUARD WORLD FUND | 0,03% | 385.422 SH | 19. August 2026 | Täglich |
| FHLC · FIDELITY COVINGTON TRUST | 0,02% | 50.707 NS | 30. April 2026 | N-PORT |
| ISCB · iShares Trust | 0,02% | 5.883 SH | 19. August 2026 | Täglich |
| UWM · ProShares Trust | 0,02% | 4.087 NS | 31. Mai 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0,02% | 5.693 NS | 30. April 2026 | N-PORT |
| GSSC · Goldman Sachs ETF Trust | 0,02% | 12.727 NS | 31. Mai 2026 | N-PORT |
| URTY · ProShares Trust | 0,02% | 4.136 NS | 31. Mai 2026 | N-PORT |
| WSML · iShares Trust | 0,01% | 6.761 SH | 19. August 2026 | Täglich |
| DFAC · Dimensional ETF Trust | 0,01% | 319.151 NS | 30. April 2026 | N-PORT |
| AVIE · AMERICAN CENTURY ETF TRUST | 0,01% | 70 NS | 31. Mai 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,01% | 17.865 NS | 30. April 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,01% | 4.295 NS | 31. Mai 2026 | N-PORT |
| HDG · ProShares Trust | 0,01% | 104 NS | 31. Mai 2026 | N-PORT |
| ONEQ · Fidelity Commonwealth Trust | 0,01% | 40.956 NS | 31. Mai 2026 | N-PORT |
| DFSU · Dimensional ETF Trust | 0,00% | 6.589 NS | 30. April 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,00% | 32.357 NS | 30. April 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,00% | 37.911 NS | 30. April 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 197.760 SH | 19. August 2026 | Täglich |